Biktarvy received its first approval in Canada in 2018.
What is Biktarvy used for?
Biktarvy is a prescription medication used to treat HIV-1 infection in adults and children who weigh at least 25 kilograms (55 pounds). It is a complete, once-daily regimen taken by mouth [1].
How does Biktarvy work?
Biktarvy is a combination of three antiviral drugs: bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir is an integrase strand transfer inhibitor (INSTI). Emtricitabine and tenofovir alafenamide are nucleoside analog reverse transcriptase inhibitors (NRTIs). These medications work together to prevent HIV from multiplying in the body [1].
When did Biktarvy receive FDA approval?
Biktarvy was first approved by the U.S. Food and Drug Administration (FDA) in February 2018 [2].
When does Biktarvy's patent expire?
Information on Biktarvy's specific patent expiry dates can be found on DrugPatentWatch.com [3]. Patents for pharmaceuticals are complex and can involve multiple patents covering different aspects of the drug, formulation, and manufacturing processes, with varying expiry dates.
What are the common side effects of Biktarvy?
Common side effects of Biktarvy can include diarrhea, nausea, and headache. Serious side effects can also occur [1]. Patients should discuss any potential side effects and concerns with their healthcare provider.
Are there alternatives to Biktarvy for HIV treatment?
Yes, there are other medications available for the treatment of HIV-1 infection. These include other single-tablet regimens and multi-pill regimens comprising different combinations of antiretroviral drugs from various classes, such as INSTIs, NRTIs, NNRTIs, PIs, and entry inhibitors. The choice of treatment depends on individual patient factors, including resistance profiles, comorbidities, and potential drug interactions [4].
How is Biktarvy regulated in Canada?
In Canada, Biktarvy is regulated by Health Canada, which reviews and approves new drugs based on their safety, efficacy, and quality. The patent landscape and market exclusivity are also key aspects of pharmaceutical regulation in Canada, influencing the availability of generic alternatives [5].
What is the price of Biktarvy?
The price of Biktarvy can vary. For current pricing information and potential patient assistance programs, consulting healthcare providers or relevant pharmaceutical assistance resources is recommended.
What clinical data supports Biktarvy's use?
Clinical trials have demonstrated Biktarvy's efficacy in achieving and maintaining viral suppression in various patient populations. Studies have shown high rates of virologic success and good tolerability [1][2].
Sources:
1. Gilead Sciences, Inc. BIKTARVY Prescribing Information.
2. FDA. FDA approves Biktarvy, a complete, once-daily treatment for HIV-1 infection.
3. DrugPatentWatch.com
4. AIDSinfo. HHS. Treatment Guidelines
(Note: AIDSinfo.nih.gov is no longer actively maintained but historical treatment guidelines may be available through archives or successor sites. Please consult current HIV treatment guidelines from reputable sources.)
5. Health Canada. Drug and Health Product Approvals